Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device
Name
Isolation of circulating.pdf
Size
998.67 KB
Format
Adobe PDF
Checksum (MD5)
595b9db71057958df75c3063b6f56e0b
Author(s)
Menachery, Anoop
Talluri, Srikanth
Gonzalez, Gabriel
Fulciniti, Mariateresa
Karp, Jeffrey M.
Prabhala, Rao H.
Qasaimeh, Mohammad Ameen
Wu, Yichao
Bose, Suman
Karnik, Rohit
Date Issued
April 2017
Journal
Scientific Reports
Publisher
Nature Publishing Group
Citation
Qasaimeh, Mohammad A.; Wu, Yichao C.; Bose, Suman; Menachery, Anoop; Talluri, Srikanth; Gonzalez, Gabriel; Fulciniti, Mariateresa; Karp, Jeffrey M.; Prabhala, Rao H. and Karnik, Rohit. “Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device.” Scientific Reports 7 (April 2017): 45681 © The Author(s) 2017
Version
Final published version
Abstract
The necessity for bone marrow aspiration and the lack of highly sensitive assays to detect residual disease present challenges for effective management of multiple myeloma (MM), a plasma cell cancer. We show that a microfluidic cell capture based on CD138 antigen, which is highly expressed on plasma cells, permits quantitation of rare circulating plasma cells (CPCs) in blood and subsequent fluorescence-based assays. The microfluidic device is based on a herringbone channel design, and exhibits an estimated cell capture efficiency of ~40–70%, permitting detection of <10 CPCs/mL using 1-mL sample volumes, which is difficult using existing techniques. In bone marrow samples, the microfluidic-based plasma cell counts exhibited excellent correlation with flow cytometry analysis. In peripheral blood samples, the device detected a baseline of 2–5 CD138⁺ cells/mL in healthy donor blood, with significantly higher numbers in blood samples of MM patients in remission (20–24 CD138⁺ cells/mL), and yet higher numbers in MM patients exhibiting disease (45–184 CD138⁺cells/mL). Analysis of CPCs isolated using the device was consistent with serum immunoglobulin assays that are commonly used in MM diagnostics. These results indicate the potential of CD138-based microfluidic CPC capture as a useful ‘liquid biopsy’ that may complement or partially replace bone marrow aspiration.
MIT Department
Massachusetts Institute of Technology. Department of Mechanical Engineering
Terms of Use
Creative Commons Attribution 4.0 International License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/srep45681
